ClinicalTrials.gg
CompletedNCT02876237PROGERADUpdated Oct 30, 2026Results posted

Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer

An interventional study of geriatric assessment and quality of life and Radiotherapy in Prostate Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 10 sites in France. Open to male participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Other

How we know

Updated Oct 30, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Not applicable
Ages
75 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest — 2 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Institut Cancerologie de l'Ouest.

Started
2015
the only one that year
No phase
6 of 11
1 open now
Registered
3rd of 11
by date

Among the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, this one is the only one that started in 2015, is one of 6 with no phase, and was the 3rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 75 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, or all of them as a file.
02

Study summary

The investigators propose to carry out a prospective analysis of physical impact, psychological, cognitive and social of radiotherapy in all patients over 75 years bearer of localized prostate cancer with an indication of curative radiotherapy. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities . The quality of life of patients will be evaluated by the QLQ C30 (Quality of Life Questionnaire) European Organisation for Research and Treatment of Cancer (EORTC) before starting treatment, at the end of radiotherapy (2 months) and at 6 months. This short follow-up period seems appropriate in this elderly population and will allow an answer within 2 years to the problem raised in clinical practice.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Man with a proven prostate cancer
  2. Indication of a curative intent radiotherapy
  3. Age ≥ 75 years
  4. Patient who signed an

Exclusion criteria

Exclusion Criteria:

  1. Patient with prostate cancer
  2. Patient unable to submit to monitoring of the protocol for social, geographical or family reasons
  3. A person who is not affiliated to a social security scheme or of such a scheme
  4. Patient under trusteeship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    geriatric assessment and quality of life

    Included patient must have a geriatric assessment before radiotherapy and 6 months later. Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.

    Other: geriatric assessment and quality of life · Radiation: Radiotherapy

Interventions

  • Othergeriatric assessment and quality of life

    Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities . Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.

  • RadiationRadiotherapy

    standard radiotherapy

06

What researchers measure

Primary outcomes

  1. Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Change in global health status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), scored from 0 to 100. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.

    Time frame: From baseline to 2 months after radiotherapy

Secondary outcomes

  1. Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Change in Global Health Status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better quality of life. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.

    Time frame: From baseline to 6 months after radiotherapy

07

Results

Posted Oct 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneGeriatric Assessment and Quality of Life
Started208
Completed208
Not completed0

Outcome measures

PrimaryChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

Change in global health status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), scored from 0 to 100. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.

Time frame:
From baseline to 2 months after radiotherapy
Reported as:
Count of participants · Participants
Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
ParticipantsGeriatric Assessment and Quality of Life
Deterioration ≥ 10 points55
Stable (±10 points)95
Improvement ≥ 10 points40
SecondaryChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

Change in Global Health Status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better quality of life. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.

Time frame:
From baseline to 6 months after radiotherapy
Reported as:
Count of participants · Participants
Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
ParticipantsGeriatric Assessment and Quality of Life
Deterioration ≥ 10 points45
Stable (±10 points)100
Improvement ≥ 10 points36

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Geriatric Assessment and Quality of Life0/208 (0%)0/208 (0%)0/208 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Geriatric Assessment and Quality of Life
Overall — 75-79 year154
Overall — 80-84 year49
Overall — 85 year5
Sex: Female, Male
Sex: Female, Male(Participants)Geriatric Assessment and Quality of Life
Female0
Male208
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Geriatric Assessment and Quality of Life
Region of Enrollment
Region of Enrollment(Participants)Geriatric Assessment and Quality of Life
France208
08

Study locations

10 sites
  • Institut de Cancérologie de l'Ouest
    Angers, 49055, France
  • Hopital Henri Mondor
    Créteil, 94000, France
  • Centre Georges François Leclerc
    Dijon, 21079, France
  • CHD
    La Roche-sur-Yon, 85925, France
  • Centre Hospitalier Bretagne Sud
    Lorient, 56100, France
  • Centre Catherine de Sienne
    Nantes, 44202, France
  • Clinique Armoricaine de Radiologie
    Saint-Brieuc, 22015, France
  • CHP
    Saint-Grégoire, 35760, France
  • Clinique Mutualiste de l'Estuaire
    Saint-Nazaire, 44606, France
  • Institut de Cancérologie de Loire
    Saint-Priest-en-Jarez, 42270, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Feb 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2026, 9 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2016
First posted
Aug 23, 2016
Start
Feb 2015
Primary completionActual
Feb 2017
CompletionActual
Aug 2017
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 France)
  • Hopital Henri Mondor · Créteil, France
  • CHD · La Roche-sur-Yon, France
  • Clinique Armoricaine de Radiologie · Saint-Brieuc, France
  • CHP · Saint-Grégoire, France
  • Clinique Mutualiste de l'Estuaire · Saint-Nazaire, France
  • Institut de Cancérologie de Loire · Saint-Priest-en-Jarez, France
Show 6 removed
  • Hopital Henri Mondor · Creteil, France
  • CHD · La Roche Sur Yon, France
  • Clinique Armoricaine de Radiologie · St Brieuc, France
  • CHP · St Gregoire, France
  • Clinique Mutualiste de l'Estuaire · St Nazaire, France
  • Institut de Cancérologie de Loire · St Priest En Jarez, France
Oct 30, 2026
Enrollment
230→208
Oct 30, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)Time frame: From baseline to 2 months after radiotherapy
  • RemovedGeneral tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaireTime frame: 2 months
  • RemovedComplete geriatric assessmentTime frame: 6 months
  • RemovedGeneral tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaireTime frame: 6 months
Oct 30, 2026
Documents
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)Time frame: From baseline to 6 months after radiotherapy
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    6 sites added, 6 sites removed
    Show 6 added (6 France)
    • Hopital Henri Mondor · Créteil, France
    • CHD · La Roche-sur-Yon, France
    • Clinique Armoricaine de Radiologie · Saint-Brieuc, France
    • CHP · Saint-Grégoire, France
    • Clinique Mutualiste de l'Estuaire · Saint-Nazaire, France
    • Institut de Cancérologie de Loire · Saint-Priest-en-Jarez, France
    Show 6 removed
    • Hopital Henri Mondor · Creteil, France
    • CHD · La Roche Sur Yon, France
    • Clinique Armoricaine de Radiologie · St Brieuc, France
    • CHP · St Gregoire, France
    • Clinique Mutualiste de l'Estuaire · St Nazaire, France
    • Institut de Cancérologie de Loire · St Priest En Jarez, France
    Enrollment 230→208
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)Time frame: From baseline to 2 months after radiotherapy
    • RemovedGeneral tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaireTime frame: 2 months
    • RemovedComplete geriatric assessmentTime frame: 6 months
    • RemovedGeneral tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaireTime frame: 6 months
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)Time frame: From baseline to 6 months after radiotherapy
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02876237
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Feb 2015
Primary completion
Feb 2017
Completion
Aug 2017
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Aurore GOINEAU, MD
principal investigator · Institut de Cancerologie de l'Ouest
Stéphane SUPIOT, MD
principal investigator · Institut de Cancérologie de l'Ouest

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion